WO2025233685 - INTRAVENOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/233685
Publication Date
13.11.2025
International Application No.
PCT/IB2025/000265
International Filing Date
09.05.2025
Title **
[English]
INTRAVENOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
[French]
FORMULATIONS D'ANTAGONISTES DE FCRN INTRAVEINEUX ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
ARGENX BV
Inventors
BORGIONS, Filip
DE MUYNCK, Cassandra
SZAKADY, Emöke
STALS, Hilde
NOUKENS, Jan
LABARRE, Michael, James
AGHA, Sofiane
Priority Data
63/645,349
10.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7664 | |
| EPO | Filing, Examination, Granting | 219851 | |
| Japan | Filing, Examination, Granting | 5346 | |
| South Korea | Filing, Examination, Granting | 13204 | |
| USA | Filing, Examination, Granting | 47640 |
Total:
293,705
Contact Us
Abstract[English]
Provided herein are pharmaceutical compositions comprising an FcRn antagonist (e.g., efgartigimod, or a biosimilar version thereof) and methods of use thereof for reducing the serum IgG level of a subject in need thereof (e.g., a subject having an autoimmune disease such as generalized myasthenia gravis (gMG)).[French]
L'invention concerne des compositions pharmaceutiques comprenant un antagoniste de FcRn (par exemple, efgartigimod, ou une version biosimilaire de celui-ci) et des procédés d'utilisation de celles-ci pour réduire le taux d'IgG sérique d'un sujet en ayant besoin (par exemple, un sujet atteint d'une maladie auto-immune telle qu'une myasthénie grave généralisée (gMG)).